Impact of beam-hardening corrections on proton relative stopping power estimates from single- and dual-energy CT.

A major contributing factor to proton range uncertainty is the conversion of computed tomography (CT) Hounsfield units (HU) to proton relative stopping power (RSP). This uncertainty is heightened in the presence of X-ray beam-hardening artifact (BHA), which has two manifestations: cupping and streaking, especially in and near bone tissue. This uncertainty can affect the accuracy of proton RSP calculation for treatment planning in proton radiotherapy.

Accuracy of proton stopping power estimation of silicone breast implants with single and dual-energy CT calibration techniques.

A major contributing factor to proton range uncertainty is the conversion of computed tomography (CT) Hounsfield Units (HU) to proton relative stopping power (RSP). This uncertainty is elevated with implanted devices, such as silicone breast implants when computed with single energy CT (SECT). In recent years, manufacturers have introduced implants with variations in gel cohesivity.

Solution of the Michaelis-Menten equation using the decomposition method.

We present a low-order recursive solution to the Michaelis-Menten equation using the decomposition method. This solution is algebraic in nature and provides a simpler alternative to numerical approaches such as differential equation evaluation and root-solving techniques that are currently used to compute substrate concentration in the Michaelis-Menten equation. A detailed characterization of the errors in substrate concentrations computed from decomposition, Runge-Kutta, and bisection methods over a wide range of s(0) : K(m) values was made by comparing them with highly accurate solutions obtained using the Lambert W function.

Establishing a threshold for 131I bioassay in nuclear medicine personnel.

Since the late 1970's, manufacturers in nuclear medicine have reformulated the I solution to reduce the volatility of the iodine. There has also been an increase in use of the iodide in encapsulated form. Per the requirement of the current U.

The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.

Currently, an accepted post-surgical treatment of patients with thyroid carcinoma is administration of an ablative dose of I. This treatment is well established based on extensive experience and modeling. However, for patients with renal disease, reduced iodine removal rates result in controversial thyroid doses and potentially excessive red bone marrow doses.